ng28ÄϹ¬

ÌõÄ¿µÄ

ng28ÄϹ¬Óë°ÙÁ¦Ë¾¿µ¾ÍBB-1701¸æ¿¢¾ßÓÐÕ½ÂÔÏàÖúÑ¡ÔñȨµÄÁªºÏ¿ª·¢Ð­Òé

ng28ÄϹ¬Öêʽ»áÉç(×ܲ¿£º¶«¾©£¬Ê×ϯִÐй٣ºÄÚÌÙÇç·ò£¬”ng28ÄϹ¬”£©Ðû²¼£¬ÒÑÓë°ÙÁ¦Ë¾¿µÉúÎïÒ½Ò©£¨º¼ÖÝ£©ÓÐÏÞ¹«Ë¾£¨×ܲ¿£ºÖйúÕã½­Ê¡£¬¡°°ÙÁ¦Ë¾¿µ¡±£©¾Í¿¹ÌåżÁªÒ©£¨ADC£©BB-1701¸æ¿¢ÁªºÏ¿ª·¢Ð­Ò飬²¢ÓµÓÐÕ½ÂÔÏàÖúµÄÑ¡ÔñȨ¡£

¡°Ïû»¯µÀð¤Ä¤½²Ê¦ÍÅ¡±ÔÚ¾©½¨Á¢

ËÄÔ£¬²»Ö¹´ºÅ¯£¬ÇÒÓл¨¿ª¡£ÐÂÄêÐÂÆøÏ󣬡°Ïû»¯µÀð¤Ä¤½²Ê¦ÍÅÈ«¹úÆô¶¯»á¡±´îÔØ×Å2023±±¾©Ð­ºÍ¹ú¼ÊÏû»¯¼²²¡ÂÛ̳£¬ÓÚ4ÔÂ14ÈÕÔÚ±±¾©ÄÚÃɹŴóÏáÖØÕÙ¿ª¡£

ng28ÄϹ¬ÈÕ±¾Öþ²¨Ñо¿ÊµÑéÊÒÖØ´ó¸ïÐÂÍê³É

½«×÷ΪÁ¬½ÓÈËÓëÈË¡¢ÓëÊý¾ÝºÍÓëÊÀ½çµÄÈ«ÇòÒ©ÎïÑз¢ÖÐÐÄ

ng28ÄϹ¬½«ÔÚ2023ÄêSGOÅ®ÐÔ°©Ö¢Äê¶È¼¯»áÉÏÐû²¼Ö×ÁöѧÏà¹ØµÄÑо¿½á¹û

3ÔÂ24ÈÕ£¬ng28ÄϹ¬Ïò2023Ä긾¿ÆÖ×Áöѧ»á£¨SGO£©Å®ÐÔ°©Ö¢Äê»áÌá½»ÁËÁ½·Ý±¨¸æ£¬¸Ã¼¯»á½«ÓÚ3ÔÂ25ÈÕÖÁ28ÈÕÔÚ·ðÂÞÀï´ïÖÝ̹ÅÁÊоÙÐУ¬²¢ÒÔÍøÂç·½·¨½øÐÐÖ±²¥¡£

ÔÚAD/PD? 2023Äê¶È¼¯»áÉÏ£¬ng28ÄϹ¬½«Õ¹Ê¾°üÀ¨Äþ¾²ÐÔÆÀ¹À¡¢ÁÙ´²Ð§¹ûºÍÉú»îÖÊÁ¿·½ÃæÂØ¿¨Ä¹ÐÂÊý¾ÝÒÔ¼°ÆäËüÖØÒª°¢¶û´Äº£Ä¬²¡£¨AD£©Ñо¿Çé¿ö

±¾´ÎÐû²¼µÄÐÅÏ¢ÊÇÀ´×Ông28ÄϹ¬ÂØ¿¨Ä¹ IIIÆÚÔçÆÚ°¢¶û´Äº£Ä¬²¡È·Ö¤ÐÔADÑо¿ÖУ¬»¼ÕßÔÚ±¬·¢ARIA£¨µí·ÛÑùÂÑ°×Ïà¹Ø³ÉÏñÒì³££©Ê±Ê¹Óÿ¹ÑªÐ¡°å»ò¿¹ÄýÒ©£¬¼°·¢Ã÷µ¥¶ÀµÄARIA-HÎÊÌâ¡£

ng28ÄϹ¬ÈÙ»ñ2023ÄêJ-Win Diversity Award¡¸»ùʯ³É¼¨´ó½±¡¹

3ÔÂ10ÈÕ£¬ng28ÄϹ¬Öêʽ»áÉçÔÚÓÉ·ÇÓªÀû×éÖ¯¡ª¡ªÈÕ±¾Å®ÐÔÁ¢ÒìÍøÂ磨NPO J-Win£©¾Ù°ìµÄ¡°2023 J-Win Diversity Award¡±ÖУ¬ÈÙ»ñ¡¸»ùʯ³É¼¨´ó½±¡¹¡£

ng28ÄϹ¬µÚÎå´ÎÈÙ»ñ¡¸½¡¿µ¾­ÓªÓÅÁ¼·¨ÈË¡«´óÐÍÆóÒµWhite500¡«¡¹È϶¨

3ÔÂ7ÈÕ£¬ng28ÄϹ¬Öêʽ»áÉçÈÙ»ñÓÉÈÕ±¾¾­¼Ã¹¤ÒµÊ¡ÓëNippon Kenko KaigiÌᳫµÄ2023Ä꡸½¡¿µ¾­ÓªÓÅÁ¼·¨ÈË¡«´óÐÍÆóÒµWhite500¡«¡¹È϶¨¡£¸ÃÏîÄ¿×Ô2017ÄêÆð¿ªÊ¼Ê©ÐУ¬½ñÄêÊÇng28ÄϹ¬µÚÎå´Î»ñµÃ¸ÃÏîÊâÈÙ¡£

FDA½ÓÊÜng28ÄϹ¬Ìá½»µÄÔö²¹ÉúÎïÖƼÁÐí¿ÉÉêÇ룬²¢ÊÚÓèLEQEMBI?¹Å°åÉóÅúÓÅÏÈÉóÆÀ×ʸñ

FDA½«ÆÀ¹ÀÑéÖ¤ÐÔIIIÆÚClarity ADÊý¾Ý£¬ÒÔÈ·¶¨ÊÇ·ñ½«LEQEMBI?µÄ¼ÓËÙÉóÅúת»»Îª¹Å°åÉóÅú
ÓÅÏÈÉóÆÀ½«ÓÚ2023Äê7ÔÂ6ÈÕͨ¹ý¡¶´¦·½Ò©Ê¹ÓÃÕ߸¶·Ñ·¨°¸ ¡·(PDUFA)£¬¼ÓËÙFDAµÄÉó²éʱ¼ä

ng28ÄϹ¬ºÍ²³½¡µÄÂØ¿¨Ä¹±»¹ú¼ÒÒ©Æ·¼à¶½ÖÎÀí¾ÖÄÉÈëÓÅÏÈÉóÆÀ

ng28ÄϹ¬ºÍ²³½¡½ñÈÕÐû²¼£¬Öйú¹ú¼ÒÒ©Æ·¼à¶½ÖÎÀí¾Ö½«ÉúÎïÖÆÆ·ÉÏÊÐÉêÇëÂØ¿¨Ä¹£¨lecanemab£¬Ó¢ÎÄÉÌÆ·Ãû£ºLEQEMBI?£©ÄÉÈëÓÅÏÈÉóÆÀ£¬ÕâÊÇÒ»ÖÖ¿¹µí·ÛÑùÂÑ°× (A¦Â) Ô­ÏËά¿¹Ìå¡£¹ú¼ÒÒ©Æ·¼à¶½ÖÎÀí¾Ö½«Æô¶¯ÓÅÏÈÉóÆÀºÍÅú×¼³ÌÐò£¬Ö¼ÔÚ¼ÓËÙ¾ßÓÐÖØ´óÁÙ´²¼ÛÖµµÄÐÂÒ©µÄÑз¢ºÍÉÏÊС£Æ¾¾Ý¸Ã³ÌÐò£¬Ô¤¼Æ½«Ëõ¶ÌÉóÆÀʱ¼ä¡£

ÈÕ±¾ºñÉúÀͶ¯Ê¡½«ÂØ¿¨Ä¹ÄÉÈëÓÅÏÈÉóÆÀ

ng28ÄϹ¬ºÍ²³½¡½ñÈÕÐû²¼£¬ÈÕ±¾ºñÉúÀͶ¯Ê¡½«ÉúÎïÖÆÆ·ÂØ¿¨Ä¹£¨lecanemab£¬²úÆ·Ãû£ºLEQEMBI?£©ÄÉÈëÓÅÏÈÉóÆÀ£¬ÕâÊÇÒ»ÖÖ¿¹µí·ÛÑùÂÑ°× (A¦Â) Ô­ÏËά¿¹Ìå¡£ºñÉúÀͶ¯Ê¡¹ØÓÚÑÏÖؼ²²¡¾ßÓиßÒ½ÁÆЧÓõÄÐÂÒ©ÊÚÓèÓÅÏÈÉóÆÀ£¬×ÜÉóÆÀÖÜÆÚ½«Ëõ¶Ì¡£

ÍøÕ¾µØͼ